Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9044354 | 1.00 | MEN1 (0.37) | MEN1KMT2ASLC6A3NPSR1SMN1; SMN2 | |
| SCHEMBL4300719 | 1.00 | MEN1 (0.37) | MEN1KMT2ASLC6A3NPSR1SMN1; SMN2 | |
| SCHEMBL4300724 | 1.00 | MEN1 (0.37) | MEN1KMT2ASLC6A3NPSR1SMN1; SMN2 | |
| SCHEMBL9213202 | 1.00 | MEN1 (0.37) | MEN1KMT2ASLC6A3NPSR1SMN1; SMN2 | |
| SCHEMBL5686664 | 0.91 | SMN1; SMN2 (0.40) | MEN1KMT2ASLC6A3NPSR1SMN1; SMN2 | |
| SCHEMBL27328368 | 0.87 | MEN1 (0.35) | MEN1KMT2ASLC6A3NPSR1HPGD | |
| SCHEMBL17265224 | 0.86 | MEN1 (0.34) | MEN1KMT2ASLC6A3NPSR1HPGD | |
| SCHEMBL17267071 | 0.84 | MEN1 (0.33) | MEN1KMT2ASLC6A3NPSR1HPGD | |
| SCHEMBL29397857 | 0.84 | EPHX1 (0.33) | MEN1KMT2ASLC6A3NPSR1HPGD | |
| SCHEMBL18600852 | 0.83 | MEN1 (0.35) | MEN1KMT2ASLC6A3NPSR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239778-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-18 | — | — | US | disclosed |
| US-11993593-B2 | Griseofulvin compound and pharmaceutical use thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-28 | — | — | US | disclosed |
| US-20240150309-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-117897384-A | CDK2 inhibitors | 缆图药品公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4308570-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425661-A | Macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2024-01-19 | — | — | CN | disclosed |
| US-11834427-B2 | Griseofulvin compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-20230136988-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20220411416-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| EP-4032883-A1 | GRISEOFULVIN COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2022-07-27 | — | — | EP | disclosed |
| US-20190092741-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-03-28 | — | — | US | disclosed |
| EP-3438103-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-7582781-B2 | epoxidation to produce 1,2-Epoxy-2-(2,4-difluorophenyl)butan-3-ol intermediate for pharmaceutical drugs, a triazole antifungal agent | KANEKA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20060155136-A1 | Optically active halohydrin derivative and process for producing optically active epoxy alcohol derivative from the same | KANEKA CORPORATION (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1647551-A1 | OPTICALLY ACTIVE HALOHYDRIN DERIVATIVE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE EPOXY ALCOHOL DERIVATIVE FROM THE SAME | KANEKA CORPORATION (JP) | 2006-04-19 | — | — | EP | disclosed |
| US-6720463-B1 | REDUCING AN ALKYLHYDROXYESTER WITH EASY TO HANDLE SODIUM BOROHYDRIDE; MAINTAINING OPTICAL ACTIVITY | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2004-04-13 | — | — | US | disclosed |
| EP-1146032-A1 | PROCESS FOR THE PRODUCTION OF ALKANEDIOL DERIVATIVES | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2001-10-17 | — | — | EP | disclosed |
| EP-0728752-A1 | Triazole compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-08-28 | — | — | EP | disclosed |
| US-5405861-A | Fungicides | TAKEDA CHEMICAL INDUSTRIES, CO., LTD. (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0421210-A2 | Triazole compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060155136-A1 | Optically active halohydrin derivative and process for producing optically active epoxy alcohol derivative from the same | TALDO1, CYP51A1, ERG28 | MEN1 3817/4885KMT2A 2433/4885SLC6A3 2434/4885 |
| US-11834427-B2 | Griseofulvin compound | PTGS1, CYP11B1, GRIA1 | MEN1 2215/4885KMT2A 3933/4885SLC6A3 2434/4885 |
| US-20240239778-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | ACBD3, NR3C1, GRN | MEN1 654/4885KMT2A 4235/4885SLC6A3 1728/4885 |
| US-20240150309-A1 | GRISEOFULVIN COMPOUND | PTGS1, CYP11B1, GRIA1 | MEN1 2215/4885KMT2A 3933/4885SLC6A3 2434/4885 |
| US-20230136988-A1 | GRISEOFULVIN COMPOUND | PTGS1, CYP11B1, GRIA1 | MEN1 2215/4885KMT2A 3933/4885SLC6A3 2434/4885 |
| US-20190092741-A1 | GRISEOFULVIN COMPOUND | PTGS1, CYP11B1, GRIA1 | MEN1 2215/4885KMT2A 3933/4885SLC6A3 2434/4885 |
| US-11993593-B2 | Griseofulvin compound and pharmaceutical use thereof | ACBD3, GRN, C1S | MEN1 632/4885KMT2A 4213/4885SLC6A3 1713/4885 |
| US-20220411416-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | ACBD3, NR3C1, GRN | MEN1 654/4885KMT2A 4235/4885SLC6A3 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.